Mind Medicine Australia
Mind Medicine Australia logo Menu

Breaking News:
The TGA Reschedules MDMA and Psilocybin for Medical Use from Schedule 9 to Schedule 8

From July 1 2023, psilocybin and MDMA can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

Please see the TGA's Media Release for more information.

Everyone at MMA would like to say a huge THANK YOU to the tens of thousands of people around Australia and internationally who have supported us in pursuing this rescheduling. We couldn't have done it without you. We also acknowledge the TGA for their foresight in building a healthier and happier Australia.

More info coming soon.

An Important Message to the Prime Minister

Short video (4 min)

Full length video (15 min)

Vanessa tragically lost her husband Franco to suicide after a 3 year battle with severe treatment resistant depression. She had hoped that her husband would gain access to Psychedelic-Assisted Therapies in Australia. On November 7 2022 she delivered a letter to her local member and Prime Minister of Australia Anthony Albanese, sharing her story and asking for his help to ensure Psychedelic-Assisted Therapies could be made available to the millions who are suffering.

Please read Vanessa's Letter and share it far and wide. Together we can create change.

Read Letter (PDF, 1.8 MB)

Preventing Suicide and Suffering

Learn more

Please help people who are suffering with mental illness by supporting the development of psychedelic-assisted psychotherapy in Australia.


Mind Medicine Australia (MMA) is a charity that seeks to alleviate the suffering caused by mental illness in Australia through expanding the treatment options available to medical practitioners and their patients. We are focused on the development of safe and effective psychedelic-assisted therapies to cure a range of mental illnesses.

Apply now for our Certificate in Psychedelic-Assisted Therapies (CPAT)

Learn more

Everyone in need should be able to access psychedelic-assisted therapies in medically controlled environments

Our progress to date

Through the work of MMA and our many supporters we are helping medical practitioners who are seeking approvals at the Commonwealth Government level (via the TGA's Special Access Scheme-B pathway) so that they can prescribe the use of medical grade psilocybin and medical grade MDMA as part of a short course of psychotherapy in medically controlled environments for individual consenting patients suffering from treatment-resistant depression or treatment-resistant Post-Traumatic Stress Disorder. A significant number of these approvals have now been given by the TGA. However, barriers remain at the State and Territory levels around Australia because of a legislative failure within these jurisdictions to distinguish between the recreational and medical use of these substances.

We also run the Certificate in Psychedelic-Assisted Therapies (CPAT) course for mental health practitioners, the only course of its kind in the Southern Hemisphere. This is crucial to ensuring that we have a pool of highly trained medical practitioners and therapists to provide these treatments when all necessary government approvals have been given. We have already trained nearly 100 health practitioners and we expect to train a further 200 in 2022. The world class course Faculty is led by two outstanding clinical leaders and contains many of the leading researchers, psychiatrists, therapists, pharmacologists, researchers and other clinical experts in this field globally. The testimonials that we have received from participants about the quality and relevance of the course have been outstanding.

We will again apply for the rescheduling of medical grade psilocybin and medical grade MDMA when used as part of therapy in medically controlled environments from Schedule 9 (Prohibited Substances) to Schedule 8 (Controlled Medicines) of the Commonwealth Government's Standard for the Uniform Scheduling of Medicines and Poisons (often referred to as the Poisons Standard). Rescheduling will open up legislative permit pathways in individual States and Territories around Australia to enable medical practitioners who receive an approval from the TGA to use one of these medicines as part of therapy for a specific patient to also be able to apply for the necessary medical consent from the Government of the State or Territory where they and their patient reside.

Earlier this year the TGA announced the establishment of an independent inquiry to advise on whether the requirements for a Schedule 8 medicine had been established.

On 30 September 2021, the TGA published the findings of the Independent Panel Review which confirmed that research supported the conclusion that these medicines were safe and well tolerated by patients when given in a medically controlled environment and produced statistically significant results. These findings confirm the advice that we have previously received from our own experts which formed the basis of our rescheduling application.

4 March 2022

Lodgement deadline for scheduling applications

April 2022

Public notice of proposed changes to scheduling and invitation to comment

May 2022

Public submission deadline

September 2022

Public notice of interim decisions and invitation to comment

October 2022

Public submission deadline

November 2022

Public notice of final decisions

200+ Therapists in training annually

500,000+ YouTube views

33+ Local chapters

400+ Patients assisted through our Psychological Service

200+ Events to date reaching tens of thousands of people

2200+ Chapter members

75+ Advisory panel members

24,500+ Volunteer hours

Fast Facts

  • Around the world psychedelic-assisted therapies are on the cusp of widespread acceptance as a breakthrough therapy for key classes of mental illness.
  • These medicines have been shown to be very safe and non-addictive when used in a medically controlled environment.
  • These therapies are being trialed as treatments for depression, PTSD, anxiety, end-of-life distress, dementia, anorexia and opioid, alcohol and smoking addictions and a number of other illnesses.
  • These treatments are showing remission rates of up to 80% after just 2-3 medicinal doses in combination with psychotherapy.
  • There have been over 160+ trials in the past decade.
  • In the 50's/60's these medicines were considered the next big breakthrough in treatments for mental illnesses before the War on Drugs in 1970, which stopped further research for decades.
  • Both psilocybin-assisted psychotherapy for major and treatment-resistant depression as well as MDMA-assisted psychotherapy for PTSD have been granted “Breakthrough Therapy Designation” by the Food and Drug Administration (FDA) in the USA to fast-track the approval process because clinical evidence to date indicates that they may demonstrate substantial improvement over currently available therapies.
  • In the past 2 years over 40 for-profit companies have emerged in this space globally creating an entire new industry, jobs and other opportunities for innovation in treatments.

Your donation supports:

Financial Assistance Toward Practitioner Professional Development

Supporting access for practitioners to build upon their skills. This includes MMI's Certificate in Psychedelic-Assisted Therapies program, as well as shorter workshops to prepare mental health professionals for the future.

Awareness and Knowledge Building

We organise educational events, film screenings, conferences and also have local chapters open to the public.

Access to Medically Approved Therapy

We promote changes in legislation, promote legal and ethical frameworks, provide psychological support services, develop clinical rollouts and medicine manufacturing capabilities.

Engagement with University sector and novel research

Engagement with universities to promote research, development and economic analysis and rollout plans.

Support us

Sign up to the newsletter

Heartfelt thanks to our partners & major donors

Hunt family foundation logo Tony Shields logo Creative Universe logo Vasudhara logo Creative Innvation logo